What are the indications, dosing regimen, contraindications, and monitoring recommendations for teriparatide (recombinant parathyroid hormone) in adults with severe osteoporosis?

Teriparatide for Severe Osteoporosis

Teriparatide (recombinant PTH 1-34) is indicated for adults at very high risk of fracture—specifically those with severe or multiple vertebral fractures, T-score ≤-3.5, or those who have failed or are intolerant to bisphosphonates—and should be administered as 20 mcg subcutaneously once daily for up to 2 years maximum lifetime use. 1, 2, 3

Indications

Teriparatide is FDA-approved for three specific populations 3:

• Postmenopausal women with osteoporosis at high risk for fracture or who have failed/are intolerant to other therapies
• Men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed/are intolerant to other therapies
• Men and women with glucocorticoid-induced osteoporosis at high risk for fracture or who have failed/are intolerant to other therapies

When to Choose Teriparatide Over Bisphosphonates

For very high-risk patients (severe/multiple vertebral fractures), the 2019 Endocrine Society guidelines strongly recommend teriparatide or abaloparatide as first-line therapy over antiresorptives 1. The 2023 ACR guidelines for glucocorticoid-induced osteoporosis conditionally recommend PTH/PTHrP agents over bisphosphonates or denosumab specifically for very high-risk patients 4.

For glucocorticoid-induced osteoporosis, teriparatide demonstrated superiority over alendronate by increasing lumbar and hip BMD and decreasing vertebral (but not nonvertebral) fractures at 36 months 4.

Dosing Regimen

Standard dose: 20 mcg subcutaneously once daily 3

Administration details:

• Inject into the thigh or abdominal region 3
• Administer initially under circumstances where the patient can sit or lie down (risk of orthostatic hypotension with first doses) 3
• Ensure adequate calcium (1,000-1,200 mg daily) and vitamin D (maintain 25(OH)D ≥30-50 ng/mL) supplementation 4, 2

Critical duration limitation: Maximum 2 years of treatment during a patient's lifetime 3. Use beyond 2 years should only be considered if the patient remains at or has returned to very high fracture risk 3.

Pre-Treatment Assessment

Before initiating teriparatide, measure 2:

• Serum calcium
• PTH level
• 25(OH)D level
• Alkaline phosphatase (to rule out Paget disease)

Contraindications

Absolute contraindications 3:

• Hypersensitivity to teriparatide or excipients
• Open epiphyses (pediatric use contraindicated)
• Paget disease of bone
• Unexplained elevation of alkaline phosphatase
• Prior external beam or implant radiation therapy involving the skeleton
• Bone metastases or history of skeletal malignancies
• Hereditary disorders predisposing to osteosarcoma
• Primary or untreated secondary hyperparathyroidism
• Underlying hypercalcemic disorders

Important Warnings and Precautions

Osteosarcoma Risk

The FDA removed the black box warning in 2023 after extensive post-marketing surveillance found no increased risk in humans 3. The original warning was based on rat studies using supraphysiologic doses. The background incidence of osteosarcoma in women ≥50 years is approximately 1 in 250,000, and actual incidence in teriparatide users remains consistent with this background rate 2.

Hypercalcemia

• Usually mild, asymptomatic, and transient 2
• If monitoring serum calcium, draw blood at least 16 hours after drug administration 2
• Limit total daily calcium intake to 1,500 mg 2
• Discontinue if worsening cutaneous calcification develops 3

Orthostatic Hypotension

• Transient, occurs with initial doses 2
• Usually does not require discontinuation
• Responds to recumbent posture 2

Urolithiasis

Consider risk/benefit in patients with active or recent kidney stones due to risk of exacerbation 3.

Monitoring Recommendations

During treatment:

• Serum calcium after 1 month of treatment 2
• No routine monitoring required beyond this unless clinically indicated
• BMD reassessment not standardized during the 2-year treatment period

Sequential Therapy: Critical Consideration

Teriparatide must be followed by antiresorptive therapy to maintain bone density gains 1, 2. When teriparatide is stopped, bone density declines rapidly within the following year 2.

Recommended sequence:

1. Complete teriparatide course (up to 2 years)
2. Immediately transition to bisphosphonate or denosumab (no washout period needed) 2
3. If denosumab is used, it must not be stopped without transitioning to another antiresorptive to prevent rebound fractures 1

Important Sequencing Caveat

Prior bisphosphonate use blunts teriparatide's anabolic effect 4, 2. The bone anabolic response is diminished when teriparatide follows antiresorptive therapy. Ideally, teriparatide should be used first-line in very high-risk patients, not after bisphosphonate failure, though this is not always clinically feasible.

Concurrent bisphosphonate + teriparatide therapy should be avoided—it provides no additional benefit and may reduce teriparatide's efficacy 2.

Common Side Effects

Most adverse reactions are mild and transient 2:

• Arthralgia and pain (>10%)
• Nausea (>10%)
• Leg cramps
• Transient orthostatic hypotension (first few doses)

Drug Interactions

Digoxin: Transient hypercalcemia may predispose patients to digitalis toxicity; monitor accordingly 3.

Special Populations

Pregnancy: Consider discontinuing when pregnancy is recognized 3

Lactation: Breastfeeding not recommended 3

Pediatric: Safety and effectiveness not established; avoid use due to increased baseline osteosarcoma risk and open epiphyses 3

Women of childbearing potential: In glucocorticoid-induced osteoporosis, if oral bisphosphonates are inappropriate and the patient does not plan pregnancy during treatment period with effective contraception, teriparatide is preferred over denosumab 5.